Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perkin-Elmer

This article was originally published in The Gray Sheet

Executive Summary

Files a registration statement with the Securities and Exchange Commission proposing an offering of 2 mil. shares of common stock held by a Becton-Dickinson subsidiary. B-D obtained the shares when its Applied Biosystems holdings were exchanged into Perkin-Elmer shares as part of the two firms' merger ("The Gray Sheet" Oct. 12, 1992, p. 3). Following the proposed offering, B-D will have completely divested its interest in Perkin-Elmer, which will receive no proceeds from the transaction. "The sale of these securities is consistent with" B-D's policy "to maintain investments only in niche market companies," according to B-D President and CEO Raymond Gilmartin. First Boston Corporation will underwrite the offering.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel